Novartis Faces Setback in Cardiovascular Drug Trial, Impacting Market Outlook for Lp(a) Treatments
Novartis' recent failure in a key cardiovascular trial for its cholesterol drug pelacarsen has raised concerns about the viability of treatments targeting Lp(a), a cholesterol variant linked to increased heart disease risk, impacting not only Novartis but also its competitors Amgen and Eli Lilly.